Your shopping cart is currently empty

PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo. |
| In vitro | PD-L1-IN-5 (X22) exhibits no significant cytotoxic effects in vitro on MC38 and CT26 cells at concentrations ranging from 0 to 150 μM over a 12-hour period. |
| In vivo | PD-L1-IN-5 (X22), administered orally at doses of 5 or 25 mg/kg daily for 20 consecutive days, demonstrates significant antitumor activity through partial toxicity upregulation of tumor-infiltrating CD8+ T cells in mouse models of MC38 and CT26 colon cancer. However, it shows reduced antitumor effects in immunodeficient nude mice with syngeneic CT26 colorectal cancer, indicating its mechanism relies on the immune system. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.